Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its PTX-100 drug by the US Food and Drug Administration (FDA)….

Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to progress its PTX-100 and PTX-200 cancer treatment therapies.

Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M. CellPryme-M is a platform technology that produces superior cells during the cell…